Immunology
What makes immuno-oncology therapies attractive investments?
Although immuno-oncology therapies have been around for many years, investors are excited to partner with innovators in the space who can push the boundaries of what these therapies are able to achieve. A panel of investors and business development executives discussed what exactly makes a specific candidate attractive as a business opportunity during a recorded session at the Biotech Showcase virtual event.  Discuss
New immunotherapy piggybacks off polio vaccine to treat cancer
As if we needed another reason to get vaccinated, researchers have developed a technology that leverages the polio vaccine to help treat cancer for those who develop the disease later in life. The technology, conceived at Duke University and developed by Istari Oncology, uses antigens produced by the polio vaccine to trigger the immune system to eat away at targeted cancer cells.  Discuss
Regulatory Roundup: Designations come through before year's end
This week's Regulatory Roundup covers activities from November 30 to December 4 and is filled with breakthrough, orphan, and rare disease designations from the U.S. Food and Drug Administration and the European Medicines Agency. Several cancer, immunotherapy, and vaccine companies also submitted biologic license applications to move their candidates forward.  Discuss
New model could improve vaccine, immunotherapy design
A new model used to predict the outcomes of pathogen detection systems as a function of innate immunity may lead to more effective cancer immunotherapies and vaccines against existing and novel pathogens, according to results published in Cell Systems on October 27.  Discuss
Antibody fragments may be exceptionally effective against SARS-CoV-2
An engineered antibody fragment has been developed as a highly potent neutralizer of SARS-CoV-2. For the first time, one of these tiny molecules has been tested for efficacy in in vitro and in vivo infection models. The results of the collaborative study were published in Cell on September 14.  Discuss
New approach to cancer immunotherapies combines 2 mAb treatments
A new approach to increasing the effectiveness of current cancer immunotherapies combines existing therapies with new monoclonal antibodies (mAb) that block inhibitory cytokines in tumor microenvironments, allowing the body to effectively eliminate tumors. The results of the study were published in Nature Communications on September 11.  Discuss
New technique reins in inflammatory response of adjuvants
Adjuvants are often added to vaccines as a method for promoting an immune response in recipients. But what happens when that immune response goes haywire, causing too much inflammation? Researchers believe that adding an "immune potentiator" to adjuvants that strengthens the immune reaction and modulates excess inflammation could lead to vaccines that are better tolerated in humans, according to a September 9 article in Science Advances.  Discuss
New CRISPR-repressor system improves efficiency of gene therapies
Researchers have developed a CRISPR-based system that can simultaneously provide transcriptional control and gene editing on demand to improve the efficacy of gene therapies. The details were published in Nature Cell Biology on September 3.  Discuss
Study investigates pharmacogenomics of COVID-19 therapies
Human genetic variation may alter the interactions of drugs being used to treat patients with COVID-19 symptoms, resulting in a range of clinical responses -- from no effect to high toxicity in some patients, according to a study published in Nature Genomic Medicine on August 18.  Discuss
Rare immune stem cells could lead to treatments for COVID-19, cancer
Rare stem cells that give rise to neutrophils in human bone marrow could offer a path to developing treatments for diseases that involve the white blood cells, according to a new article published in Immunity on August 18.  Discuss
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter